Bluetongue virus recombinant vaccines and uses thereof
View Patent ↗The present invention encompasses BTV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing BTV antigens. The invention also encompasses recombinant vectors encoding and expressing BTV antigens, epitopes or immunogens which can be used to protect animals, such as ovines, bovines, or caprines, against BTV.
1. A composition comprising a BTV (Bluetongue Virus) VP2 antigen and a pharmaceutically or veterinarily acceptable carrier, excipient, adjuvant, or vehicles; wherein a nucleic acid sequence encoding the BTV VP2 antigen is expressed in a duckweed plant and said encoded antigen is localized to the cytoplasm of the duckweed plant; wherein said encoded antigen is non-glycosylated, and partially purified; wherein SEQ ID NO: 26 is fused immediately upstream of the nucleic acid sequence encoding the BTV VP2 antigen; and wherein the BTV VP2 antigen has at least 95% sequence identity to the sequence as set forth in SEQ ID NO: 4, and provides a protective immunogenic response in an animal against BTV infection.
2. The composition of claim 1 , wherein the composition further comprises a BTV VP5 antigen having at least 95% identity to the sequence as set forth in SEQ ID NO: 10.
3. The composition of claim 1 , wherein the BTV antigen is substantially purified.
4. The composition of claim 1 , wherein the pharmaceutically or veterinarily acceptable carrier, adjuvant, excipient, or vehicle is a crystalline salt or an oil-in-water emulsion.
5. A method of vaccinating a host susceptible to BTV comprising at least one administration of the composition according to claim 1 .
6. The method of claim 5 comprising a prime-boost administration protocol.
7. The method of claim 6 , wherein said prime-boost administration comprises a prime-administration of the composition of claim 1 , and a boost-administration of a vaccine or composition comprising a recombinant viral vector that contains and expresses the BTV antigen in vivo, or an inactivated viral vaccine comprising the BTV antigen, or a DNA plasmid vaccine or composition that contains or expresses the BTV antigen.
8. The method of claim 6 , wherein the prime-boost administration comprises a prime-administration of a vaccine or composition comprising a recombinant viral vector that contains and expresses the BTV antigen in vivo, or an inactivated viral vaccine comprising the BTV, or a DNA plasmid vaccine or composition that contains or expresses the BTV antigen, and a boost-administration of the composition of claim 1 .
9. The method of claim 6 , wherein the prime-boost administration comprises a prime-administration of the composition of claim 1 , and a boost-administration of the composition of claim 1 .
10. The method of claim 5 , wherein the host is ovine, bovine, or caprine.
11. A plasmid comprising a DNA fragment, wherein said fragment comprises SEQ ID NO: 26 fused immediately upstream of the sequence as set forth in SEQ ID NO: 3, wherein the plasmid is for duckweed plant transformation, wherein the expression of the DNA fragment in the duckweed plant produces a BTV VP2 antigen which provides a protective immunogenic response in an animal against BTV infection, and wherein said antigen is cytoplasmically localized and non-glycosylated.
12. A stably transformed duckweed plant or culture transformed with a nucleic acid sequence encoding a BTV antigen, wherein SEQ ID NO: 26 is fused immediately upstream of the nucleic acid sequence encoding the BTV antigen, wherein the BTV antigen is BTV VP2 having at least 95% sequence identity to the sequence as set forth in SEQ ID NO: 4, wherein the BTV VP2 antigen is expressed and localized to the cytoplasm of the duckweed plant or culture and non-glycosylated; and wherein said antigen provides a protective immunogenic response in an animal against BTV infection.
13. The duckweed plant or culture of claim 12 comprising the plasmid of claim 11 .
14. The composition of claim 2 , wherein the BTV VP2 has the sequence as set forth in SEQ ID NO:4, and the BTV VP5 has the sequence as set forth in SEQ ID NO:10.
15. The plasmid of claim 11 , wherein the plasmid comprises an RbcS leader sequence.
16. The plasmid of claim 11 , wherein the plasmid comprises an ADH1 intron.